60509-37-7 Usage
General Description
N-(3,4-dichlorobenzyl)butan-1-amine is a chemical compound with the molecular formula C14H18Cl2N. It is a member of the amine chemical class, and is characterized by the presence of a butyl group and a 3,4-dichlorobenzyl group. N-(3,4-dichlorobenzyl)butan-1-amine is commonly used in pharmaceutical research and drug development, particularly in the synthesis of new medications. Its potential applications may include acting as a precursor in the creation of new drugs or as a structural component in pharmaceutical formulations. Additionally, it may also be used as a reagent in organic synthesis reactions for the production of various chemical compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 60509-37-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,0,5,0 and 9 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 60509-37:
(7*6)+(6*0)+(5*5)+(4*0)+(3*9)+(2*3)+(1*7)=107
107 % 10 = 7
So 60509-37-7 is a valid CAS Registry Number.
60509-37-7Relevant articles and documents
COMPOSITION FOR DESTRUCTION OF MICROALGAE OR SPHAEROCARPUS
-
Paragraph 0141-0143, (2018/10/19)
The present disclosure relates to a composition for the destruction of microalgae or mosses. The composition for the destruction of microalgae or mosses may suppress the growth and proliferation of microalgae when treated in moss cultivation facilities, marine microalgae cultivation facilities, areas in which green or red tide is occurring, or areas in which green or red tide is expected to occur, thereby preventing damage caused by the green or red tide.
SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS
-
Page/Page column 212-213, (2012/12/13)
Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds.
